Rheumnow Podcast

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

 

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. 

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.

OP0046 Effect on SI joint structural lesions with ixekizumab
POS0058 Effect on SI joint structural lesions with bimekizumab

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Dr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!